Ground News

News from biotuesdays.com

See all of biotuesdays.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve discovered 87 headlines written by biotuesdays.com during the past 3 months.

biotuesdays.com’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is biotuesdays.com credible or reliable? Our Factuality score answers both of those questions. When it comes to biotuesdays.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about biotuesdays.com

Where is biotuesdays.com located?biotuesdays.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biotuesdays.com News

Psychedelic Drugs

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results ...

100% Center coverage: 5 sources

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s version of psilocybin could be as a depression treatment.See the Story

Canada · Canada

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

100% Right coverage: 1 sources

CAMBRIDGE, Mass. & SALISBURY, England -- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pendopharm, a division of Pharmascience Inc., the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema (HAE).See the Story

China · China

Managing Moderate to Severe COPD: Integrating New Therapies Into Practice

Panelists discuss the evolving role of newly approved chronic obstructive pulmonary disease (COPD) therapies—such as ensifentrine, mepolizumab, and dupilumab—in addressing persistent symptoms and frequent exacerbations despite standard care, highlighting their targeted use based on patient profiles, the practical challenges of integration into clinical practice, and the importance of education, shared decision-making, and personalized care to op…See the Story

Long-Term Extension Data Demonstrates Sustained Effect of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

New data reveals vidofludimus calcium effectively maintains low disability progression in relapsing-remitting multiple sclerosis over 144 weeks, enhancing patient quality of life.Multiple Sclerosis See the Story

Intensive Bevacizumab Boosts Vision in Macular Degeneration

Early and intensive treatment of age-related macular degeneration with bevacizumab is associated with greater long-term improvements in visual acuity than are ranibizumab or aflibercept, a real-world study from the Netherlands shows.Innovation See the Story

QT Imaging accelerates breast imaging with NVIDIA L40-powered software update - BioTuesdays

QT Imaging (QTCQB: QTIH) has announced the release ofits latest image reconstruction software update, version 4.4.0, significantly reducing QTscan image processing time and improving user throughput and overall efficiency. The update was developed leveraging NVIDIA’s (NASDAQ:NVDA) L40 GPU, powered by by the Ada Lovelace architecture. The FDA-cleared QTI Breast Acoustic CT scanner is the first non-invasive breast imaging technology to deliver tru…Nvidia · United States Read Article

Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD - BioTuesdays

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has added Tel Aviv Sourasky Medical Center (TASMC) to the list of clinical sites for its ongoing Phase 1/2a trial evaluating CMND-100—a proprietary MEAI-based oral drug candidate—for the treatment of alcohol use disorder (AUD). According to Clearmind, this expansion follows the recent enrollment of the trial’s first patient, announced on June 5, 2025, marking a significant milest…Israel · Israel Read Article

VeriSIM delivering predictive insights to advance and de-risk drug development - BioTuesdays

Open the article to view the coverage from biotuesdays.comInnovation Read Article

Medicus appoints Andrew Smith as COO - BioTuesdays

Medicus Pharma (NASDAQ: MDCX) has announced the appointment of Andrew Smith as chief operating officer (COO). A seasoned leader in asset management and financial operations with more than three decades of experience, Mr. Smith most recently served as the chief executive of SR Asset Management (SRAM) until its sale in 2024. He currently sits on the board of HazelTree Fund Services and is an advisor to Code Registry. “We are delighted to welcome A…Read Article

Kevin DeGeeter rejoins Ladenburg Thalmann as managing director of biotechnology equity research - BioTuesdays

Ladenburg Thalmann announced that Kevin DeGeeter has rejoined the firm as a managing director in its equity research department, effective June 2025. In this role, Mr. DeGeeter will lead equity research coverage of oncology, infectious disease, and cell therapy companies, with a focus on businesses with market capitalizations ranging from $50 million to $5 billion. Prior to rejoining Ladenburg Thalmann, he was an analyst at Oppenheimer & Co., wh…New York City · New York Read Article

ArriVent BioPharma Reports Promising Results From Phase 1b Trial for Firmonertinib in NSCLC

NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has shared encouraging interim results from its Phase 1b FURTHER trial, which investigates firmonertinib as a first-line monotherapy for non-small cell lung cancer (NSCLC) patients with EGFR PACC mutations. The findings highlight firmonertinib’s potential to address a critical gap in the treatment of this underserved population. The study reported a median progression-free survival (mP…United States · United States See the Story

News from biotuesdays.com

News from biotuesdays.com

Information about biotuesdays.com

Media Bias Ratings

Factuality

Ownership

Top biotuesdays.com News

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results ...

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

Managing Moderate to Severe COPD: Integrating New Therapies Into Practice

Long-Term Extension Data Demonstrates Sustained Effect of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Intensive Bevacizumab Boosts Vision in Macular Degeneration

QT Imaging accelerates breast imaging with NVIDIA L40-powered software update - BioTuesdays

Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD - BioTuesdays

VeriSIM delivering predictive insights to advance and de-risk drug development - BioTuesdays

Medicus appoints Andrew Smith as COO - BioTuesdays

Kevin DeGeeter rejoins Ladenburg Thalmann as managing director of biotechnology equity research - BioTuesdays

ArriVent BioPharma Reports Promising Results From Phase 1b Trial for Firmonertinib in NSCLC

Similar News Topics

Topics Most Covered by biotuesdays.com

Sources Covering Similar Topics

Breaking News Topics Related to biotuesdays.com